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To the Editor: 
Life-threatening allergic reactions are characterized by allergen-specific IgE antibodies, whereas IgG 
antibodies are a default response to an antigen exposure. Subclass 4 IgG antibodies function as 
blocking antibodies, which may suppress IgE-mediated reactions.
1
 Peanut oral immunotherapy (OIT), 
as other allergen immunotherapies, induces IgG4 antibodies.
2, 3 
We have previously shown the 
increase of IgG4 to peanut seed storage proteins, and the dose-dependent increase of IgG4- IgE ratios 
in children and adolescents receiving peanut OIT.
4, 5 
Further, we showed that IgE to the 2S albumins 
Ara h 2 and Ara h 6, which are the most important peanut allergens, 
6 
were the only IgE responses 
affected during OIT. 
5 
In this study, we screened IgG4 responses for a wide spectrum of allergens with the ISAC 
ImmunoCAP microarray in children and adolescents who underwent peanut OIT. We examined the 
IgG4 responses baseline and after OIT build-up phase with the aim of finding effects of the treatment 
on IgG4 responses to peanut-specific and cross-reactive allergens. 
The study population has been described in our previous publications.
4, 5 
Briefly, 6- to 18-
year-old children and adolescents were referred to the hospital because of peanut allergy. Of 
them, 39 with a moderate-to-severe reaction in a double-blind placebo-controlled peanut 
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challenge started OIT and 21 control patients continued to avoid peanut. During OIT, the 
daily dose of peanut protein increased from 0.1 to 800 mg in eight months. Serum samples 
were drawn at baseline and after median 12 months of OIT build-up phase or avoidance. We 
analyzed serum IgG4 (30 µl of sample) in ImmunoCAP ISAC microarrays (ThermoFisher 
Scientific; Uppsala, Sweden). We considered the detection limit 0.1 ISU-G4 also as cut-off 
for positive response. The ethics committee of Helsinki University Hospital approved the 
study. One of the parents and the patient gave a written informed consent. 
In analyzing repeated measures of the 112 allergens, we filtered the results so that in order to be 
included in the analysis an allergen had to show value above detection limit 0.1 (ISU-G4) in at least 
50% + 1 of the patients in at least one of the four groups (pre OIT, post OIT, pre avoidance, post 
avoidance). We fitted a linear model to investigate the effects of treatment, response, subject, sex, and 
age. Furthermore, we used the eBayes test for pairwise comparisons of interest. P values were 
corrected in each pairwise comparison by using the Benjamini-Hochberg procedure. We used R 
program, version 3.0 (R Project for Statistical Computing, R Foundation, Vienna, Austria; 
http://www.r-project.org/) and IBM SPSS 22 (IBM, Armonk, NY). 
Of the 39 patients on OIT, 34 achieved maintenance dosing, and 26/31 passed the double-blind 
placebo-controlled challenge with 1255 mg peanut protein. Baseline characteristics and ISAC IgE 
levels are presented in the online supplemental table 1. IgG4 levels to Ara h 1, 2, and 6 increased 
during the treatment. Avoidance group showed no changes in IgG4 levels. (Figure 1) The ingested 
cumulative protein dose during the treatment was median 71 g (range 50 mg to 158 g). The 
cumulative protein dose correlated with the increase in IgG4 to Ara h 2 (rho 0.362, P= .024), but did 
not correlate with the IgG4 increase of  
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Ara h 1 and Ara h 6.  
The IgG4-increases for Ara h 1, 2, and 6 in the 26 patients who passed the final peanut challenge, i.e. 
desensitized patients, did not differ statistically from the five non-desensitized. (Data not shown)  
Levels of other than peanut allergens that showed representative numbers of response are depicted in 
table 1, and other ISAC112 allergens in the online supplemental table 2. 
To our knowledge this is the first study to examine microarrayed IgG4 profiles in patients who 
received peanut oral immunotherapy. During the treatment, the only IgG4 levels to change were 
peanut seed storage proteins Ara h 1, 2, and 6. This is in line with our previous study were peanut OIT 
affected IgE only for the 2S albumins Ara h 2 and 6. However, in the IgG4 antibodies, the effect 
included also a third seed storage protein, Ara h 1. Studies on peanut sensitization and allergy show 
that the 7S globulin Ara h 1 is more associated with peanut allergy than the 11S globulin Ara h 3.
7, 8 
In 
our previous study, IgG4, measured with ImmunoCAP, showed increases in Ara h 1 and Ara h 3, of 
which Ara h 1-change was stronger.
5 
In the present study, Ara h 3-response in IgG4 ISAC was 
underrepresented and therefore conclusions on effects on this allergen are limited. However, the 
response rate increased from 15% before OIT to 44% after OIT. (Table 1 b) We believe that mild 
increase in Ara h 3 IgG4 in ISAC is possible.  
The findings of unaffected Ara h 8- and Ara h 9- IgG4-levels are similar to our previous study on IgE 
microarray profiles in this patient population.
5
 Ara h 8 is degraded in the gastric digestion and its’ 
effects on IgG4 levels may be therefore limited. The amount of lipid transfer protein Ara h 9 is low in 
peanut
 9
 which in turn may decrease the immunological effects of this stable allergen. Both Ara h 8- 
and 9-IgG4 responses were infrequent in our study population. 
Considering the development of tolerance, IgG4 may be the most important immunoglobulin in 
immunotherapy. Findings of this study further highlight the specificity of immunological response in 
peanut oral immunotherapy as IgG4 effects seem to occur only on the most peanut-specific allergens, 
but not on cross-reactive or unrelated allergens.  
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a) 
OIT Pre Post  P 
value 
Pre Post 
 Median Min Max Median Min Max  No of patients with 
response 
Bet v 1 0.32 0.05 3.6 0.46 0.05 3.1 .65 30 31 
Mal d 1 0.10 0.05 2.4 0.12 0.05 2.1 .85 20 22 
Bos d 8 0.50 0.05 11.4 2.3 0.05 22.4 .85 28 30 
Bos d 5 2.1 0.05 17.6 2.4 0.05 18.8 .85 36 36 
Bos d 4 2.1 0.05 21.6 0.48 0.05 13.7 .85 28 27 
Bos d 
Lactoferrin 
0.56 0.05 5.9 0.50 0.05 8.0 .85 28 30 
Gal d 1 0.88 0.05 19.6 1.1 0.05 22.6 .85 32 34 
Gal d 2 1.8 0.05 13.3 2.2 0.05 11.9 .85 33 32 
Gal d 3 0.12 0.05 0.80 0.14 0.05 0.70 .85 21 25 
Tri a aA_TI 0.28 0.05 2.9 0.26 0.05 3.2 .85 25 26 
Tri a 14 0.05 0.05 9.5 0.10 0.05 14.4 .85 19 21 
  
Avoidance Pre Post  P 
value 
Pre Post 
 Median Min Max Median Min Max  No of patients with 
response 
Bet v 1 0.26 0.05 14.1 0.16 0.05 0.90 1 15 12 
Mal d 1 0.12 0.05 2.4 0.12 0.05 1.0 1 11 10 
Bos d 8 0.74 0.05 31.0 0.32 0.05 27.9 1 19 17 
Bos d 5 3.7 0.05 25.1 2.0 0.05 19.2 1 19 17 
Bos d 4 3.7 0.05 28.9 2.7 0.05 23.5 1 19 17 
Bos d 
Lactoferrin 
0.47 0.05 1.9 0.55 0.05 1.8 1 17 15 
Gal d 1 1.5 0.05 13.6 1.6 0.05 18.1 1 18 16 
Gal d 2 3.7 0.05 19.8 2.5 0.05 24.4 1 19 17 
Gal d 3 0.24 0.05 1.2 0.16 0.05 1.4 1 16 14 
Tri a aA_TI 0.20 0.05 2.4 0.14 0.05 6.4 1 16 14 
Tri a 14 0.18 0.05 5.7 0.05 0.05 26.2 1 14 8 
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b)  
OIT Avoidance 
 Pre, n 
(%) 
Post, n  
(%) 
 Pre, n 
(%) 
Post, n  
(%) 
Ara h 1 7 (18) 27 (69)  8 (44) 6 (33) 
Ara h 2 15 (38) 37 (95) 11 (61) 7 (39) 
Ara h 3 6 (15) 17 (44) 5 (28) 3 (17) 
Ara h 6 16 (41) 37 (95) 11 (61) 10 (56) 
Ara h 8 7 (18) 10 (26) 2 (11) 0 
Ara h 9 12 (31) 12 (31) 3 (17) 4 (22) 
Table 1. a) IgG4 levels and number of patients with response (ISU-G4 ≥0.1) before and after 
treatment in oral immunotherapy (OIT) (n=39) and avoidance (n=18) groups. Allergens that 
showed representative response are included. (see methods section) b) Number of patients with 
IgG4 response (ISU-G4 ≥0.1) for peanut allergens in immunotherapy and avoidance groups. 
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Figure and supplementary table legends: 
 
Figure 1. Levels of IgG4 to peanut allergens in a) oral immunotherapy group (n=39) and b) avoidance 
group (n=18) before and after treatment. Ara h 3, Ara h 8, and Ara h 9 are excluded from the 
statistical analysis due to limited number of responses. (see Methods section) 
Supplemental table online 1. Baseline characteristics of patients in OIT (n=39) and avoidance 
(n=18) groups.  
Supplemental table online 2. Levels of IgG4 and number of patients with response (ISU-G4 ≥0.1) 
before and after peanut oral immunotherapy. Allergens with no response in any of the patients are 
excluded from the table (Amb a 1, Ani s 1, Ani s 3, Api m 1, Art v 1, Asp f 3, Asp f 6, Ber e 1, Bet v 
4, Bla g 7, Blo t 5, Che a 1, Cla h 8, Der f 2, Der p 1, Der p 2, Fag e 2, Gal d 5, Hev b 1, Hev b 3, Hev 
b 5, Hev b 6.01, Ole e 1, Pen m 2, Phl p 11, Phl p 12, Phl p 2, Phl p 7, Pla a 1, Pla l 1, Pol d 5, Tri a 
19.0101, and Ves v 5.). 
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